ChemoCentryx, autoimmune disease drug co., raises $29.84M
ChemoCentryx, a Mountain View, Calif. developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has raised $29.84 million in forth round of funding, according to a regulatory filing cited by PE Week. Glaxo Group Ltd. was joined by existing investors, including Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.
Next Story: MyUlist, for social college classifieds
Previous Story: Pulmonx, a medical device co., raises $18.5M
